Reduced expression of PHD2 prolyl hydroxylase gene in primary advanced uterine cervical carcinoma - 16/07/11
Corresponding author. Tel.: +48 61 85 46 51 0.Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 5 |
| Iconographies | 1 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Decreased PHD2 expression in human carcinomas has been considered a critical factor in supporting tumor angiogenesis and growth. We studied the levels of PHD2 transcript and protein in advanced cervical cancer specimens (n=27) and normal uterine cervical tissue samples (n=27). Real-time quantitative PCR and Western blotting analysis showed significantly lower levels of PHD2 transcript (P=0.0088) and protein (P=0.0095) in cancerous tissues as compared to corresponding normal tissue. Using DNA sequencing analysis, we also found an accumulation of mutations in promoter regions of PHD2 in advanced cervical cancer specimens. Moreover, computer analysis of these mutations showed a loss of binding sites for many transcription factors. Our results suggest PHD2 as a possible target in anti-angiogenic therapies in advanced uterine cervical carcinoma.
Le texte complet de cet article est disponible en PDF.Keywords : Cervical cancer, PHD2, Hypoxia
Plan
Vol 65 - N° 4
P. 298-302 - juillet 2011 Retour au numéro
Article précédent
- Transcriptional regulation of the chemokine co-receptor CCR5 by the cAMP/PKA/CREB pathway
- Anupam Banerjee, Vanessa Pirrone, Brian Wigdahl, Michael R. Nonnemacher
- Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin
- Renato Bonardi, Marco Tabone, Aldo Manca, Rinaldo Pellicano, Alessia Ciancio, Mario Rizzetto
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?